WDB coco Co's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 85.78.
WDB coco Co's Days Inventory for the
six
months ended in Mar. 2026 was 0.37.
WDB coco Co's Days Payable for the
six
months ended in Mar. 2026 was 11.41.
Therefore, WDB coco Co's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 74.74.
WDB coco Co (TSE:7079) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
WDB coco Co Cash Conversion Cycle Related Terms
WDB coco Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for WDB coco Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7079 vs VEEV, BTSG, TEM: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, WDB coco Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WDB coco Co Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, WDB coco Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where WDB coco Co's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
WDB coco Co's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WDB coco Co (TSE:7079) has a Cash Conversion Cycle of 74.74 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on WDB coco Co and its competitors.
Is WDB coco Co's Cash Conversion Cycle too high?
WDB coco Co's current Cash Conversion Cycle is 74.74. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.91. WDB coco Co's value of 74.74 is 317.3% above this industry median. Overall, WDB coco Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WDB coco Co's Cash Conversion Cycle compare to VEEV and BTSG?
WDB coco Co's Cash Conversion Cycle of 74.74 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.91. WDB coco Co's value of 74.74 is 317.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.91, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WDB coco Co's current Cash Conversion Cycle of 74.74 is 317.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on WDB coco Co and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WDB coco Co's current Cash Conversion Cycle is 74.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WDB coco Co stock overvalued right now?
Based on GuruFocus' analysis, WDB coco Co (TSE:7079) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,458.44, compared to a current price of 円2,572.00 — trading 25.6% below its estimated fair value. The current Cash Conversion Cycle is 74.74 and 317.3% above the Healthcare Providers & Services industry median of 17.91. WDB coco Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For WDB coco Co (TSE:7079), the current Cash Conversion Cycle is 74.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WDB coco Co (TSE:7079) Overvalued in 2026?
Based on GuruFocus' analysis, WDB coco Co stock appears to be undervalued.
The current stock price of 円2,572.00 is trading 25.6% below its estimated GF Value™ of 円3,458.44.
GuruFocus considers WDB coco Co to be Modestly Undervalued.
Key valuation signals for TSE:7079:
Cash Conversion Cycle: 74.74
GF Value™: 円3,458.44 vs. price of 円2,572.00 (25.6% below fair value)
Industry Position: 317.3% above the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:7079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WDB coco Co Ltd is a provider of safety information management for the development of pharmaceuticals and medical devices. Its services include business related to safety information management, preparation of materials related to regulatory application, QC-related work, PMS facility contract support related work, clinical research support/monitoring, and temporary staffing. The company provides Contract Research Organization services for all new drug developments, such as monitoring, safety information, data management, and statistical analysis. It provides support for the development of generic drugs, such as bioequivalence studies and biosimilars, clinical research, and physician-led clinical trials.
71GF Score
Get the complete analysis for TSE:7079
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7079 has been successfully added to your 
